Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 3, 2024
Event: Entry into a Material Definitive Agreement (At Market Issuance Sales Agreement).
Key Financial Metrics
This filing does not report operational financial results such as revenue, profit, cash flow, or margins. The primary financial metric disclosed relates to the capital raising facility:
- Aggregate Market Value Eligible for Sale: $7,350,000 (based on Form S-3 limitations).
- Commission Rate: Up to 3.0% of gross proceeds.
- Reimbursable Expenses: Up to $75,000 for counsel fees, plus $5,000 per quarter for due diligence, and $25,000 for additional prospectus supplements.
Material Changes
On July 3, 2024, iBio, Inc. entered into an At Market Issuance Sales Agreement (the "ATM Agreement") with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC. This agreement authorizes the company to sell shares of its common stock from time to time through the sales agents. The offering is subject to the effectiveness of a shelf registration statement on Form S-3 filed on the same date.
Guidance, Outlook, and Risks
- Management Commentary: The company retains control over sale parameters, including the number of shares, timing, daily limits, and minimum price thresholds. The company has no obligation to sell any shares and may suspend the offering at any time.
- Risks and Contingencies: The offering is contingent upon the effectiveness of the Form S-3 registration statement. The company explicitly states it makes no assurances that the registration statement will become effective or remain effective.
- Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 registration statement (File No. 333-280680).
- Monitor future filings for actual share issuances and proceeds generated under the ATM Agreement.
- Review the full text of the ATM Agreement (Exhibit 1.1) for specific limitations on daily sales volumes and price floors.
- Track the company's cash position to assess the necessity of utilizing this facility.